Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases

Annals of the New York Academy of Sciences

Volumn 1069, Issue , 2006, Pages 477-491

  Schedel, Jörg ^a   Gödde, Andrea ^a   Schütz, Ekkehard ^b   Bongartz, Tim A ^a   Lang, Bernhard ^c   Schölmerich, Jürgen ^a   Müller Ladner, Ulf ^a,d  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Rheumatology Outpatient Center   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

6 thioguanine nucleotide; Azathioprine; Chronic inflammatory diseases; Thiopurine methyltransferase

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADULT; AGED; ARTHRALGIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHOLESTASIS; CHRONIC INFLAMMATION; COHORT ANALYSIS; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CROHN DISEASE; DERMATOMYOSITIS; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; ENZYME ACTIVITY; EYELID EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LEUKOPENIA; LIP DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEGALOBLASTIC ANEMIA; MYALGIA; NAUSEA; PANCREATITIS; PANCYTOPENIA; RASH; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ULCERATIVE COLITIS; VASCULITIS; VOMITING; WEGENER GRANULOMATOSIS;

EID: 33745608050     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1351.048     Document Type: Conference Paper

References (44)

1. YY, D.T. et al. 1974. Lymphocyte characteristics in rheumatic patients and the effect of azathioprine therapy. Arthritis Rheum. 17: 37-45.
2. BACH, M.A. & J.C. BACH. 1972. Activities of immunosuppressive agents vitro. II. Different timing of azathioprine and methotrexate in inhibition and stimulation of mixed lymphocyte reaction. Clin. Exp. Immunol. 11: 89-98.
3. LEVY, J. et al. 1972. The effect of azathioprine on gammaglobulin synthesis in man. J. Clin. Invest. 53: 2233-2238.
4. FOX, D.A. & W.J. MC CUNE. 1994. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 20: 265-299.
5. TIEDE, I. et al. 2003. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111: 1133-1145.
6. HOMO-DELARCHE, F. et al. 1988. In vitro inhibition of prostaglandin production by azathioprine and 6-mercaptopurine. Prostaglandins 35: 479-491.
7. CHAN, G.L.C. et al. 1989. Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. Eur. J. Clin. Pharmacol. 36: 265-271.
8. CALABRESI, P. et al. 1980. Antiproliferative agents and drugs used for immunosuppression. In The Pharmacologic Basis of Therapeutics. I.S. Goodman & A. Gilman, Eds.: 265-271. Macmillian. New York.
9. GOADSBY, P.J. et al. 1986. 6-mercaptopurine-related leucopenia and in vivo xanthine oxidase activity. Lancet 2: 869-870.
10. LENNARD, L. et al. 1989. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferse genetic polymorphism. Clin. Pharmacol. Ther. 46: 149-154.
11. LENNARD, L. 1998. Clinical implications of thiopurine methyltransferase - optimization of drug dosage and potential drug interactions. Ther. Drug Monit. 20: 527-531.
12. WEINSHILBOUM, R.M. & S. SLADEK. 1980. Mercaptopurin pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Human. Genet. 32: 651-662.
13. COLLIE-DUGUID, E.S. et al. 1999. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 9: 37-42.
14. SZUMLANSKI, C.L. et al. 1992. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2: 148-159.
15. KEYSSER, M. 1993. Therapie der Rheumatoid-Arthritis (RA) mit Azathioprin-Ergebnisse einer offenen Langzeitstudie über mindestens 4 Jahre bei 528 Patienten. Z. Rheumatol. 52: 133-137.
16. SINGH, G. et al. 1989. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum. 32: 837-843.
17. LENNARD, L. & J.L. MADDOCKS. 1983. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J. Pharm. Pharmacol. 35: 15-18.
18. SCHMIEGELOW, K. & N.J. KRIEGBAUM. 1993. 6-thioguanine nucleotide accumulation in erythrocytes during azathioprine treatment for systemic connective tissue diseases: a possible index for monitoring treatment. Ann. Rheum. Dis. 52: 152-154.
19. SCHÜTZ, E. et al. 1996. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur. J. Clin. Chem. Clin. Biochem. 34: 199-205.
20. DEWIT, O. et al. 2002. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment. Pharmacol. Ther. 167: 79-85.
21. SCHÜTZ, E. et al. 1996. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther. Drug Monit. 18: 228-233.
22. ABU-SHAKRA, M. & Y. SHOENFELD. 2001. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 10: 152-153.
23. NOSSENT, H.C. & W. KOLDINGSNES. 2001. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 39: 969-974.
24. SCRIBANO, M. & C. PRANTERA. 2003. Review article: medical treatment of moderate to severe Crohn's disease. Aliment. Pharmacol. Ther. 17(Suppl 2): 23-30.
25. COROMINAS, H. et al. 2003. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology 42: 40-45.
26. CONNELL, W.R. et al. 1993. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34: 1081-1085.
27. BLACK, A.J. et al. 1998. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129: 716-718.
28. CLUNIE, G.P.R. & L. LENNARD. 2004. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology 43: 13-18.
29. MARRA, C.A. et al. 2002. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J. Rheumatol. 29: 2507-2512.
30. OH, K. T. et al. 2004. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 43: 156-163.
31. SEIDMAN, E.G. & D.E. FURST. 2002. Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine. J. Rheumatol. 29: 2484-2487.
32. SCHAEFFELER, E. et al. 2004. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14: 407-417.
33. MCLEOD, H.L. et al. 1995. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 5: 281-286.
34. DECAUX, G. et al. 2001. High 6-thioguanine nucleotide levels and low thiopurine methyltransferase activity in patients with lupus erythematosus treated with azathioprine. Am. J. Ther. 8: 147-150.
35. NAUGHTON, M.A. et al. 1999. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 38: 640-644.
36. TAI, H.L. et al. 1997. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA 94: 6444-6449.
37. ANSARI, A. et al. 2002. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16: 1743-1750.
38. DECAUX, G. et al. 2000. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J. Lab. Clin. Med. 135: 256-262.
39. DUBINSKY, M.C. et al. 2000. Pharmacogenomics and metabolite measurements of 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705-713.
40. BEST, W.R. et al. 1976. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 70: 439-444.
41. LOWRY, P.W. et al. 2001. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49: 665-670.
42. MARDINI, H.E. & G.L. ARNOLD. 2003. Utility of measuring 6-methyl-mercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J. Clin. Gastroenterol. 36: 390-395.
43. SANDERSON, J. et al. 2004. Thiopurine methyltransferse: should it be measured before commencing thiopurine drug therapy? Ann. Clin. Biochem. 41(Pt 4): 294-302.
44. ASANUMA, Y. et al. 2005. Pharmacogenetics and rheumatology. Molecular mechanisms contributing to variability in drug response. Arthritis Rheum. 52: 1349-1359.